Scholarlink

Background <p>This study aimed to evaluate the indications and real-world treatment outcomes of intravitreal bevacizumab in a resource-limited community eye hospital setting.</p> Methods <p>This retrospective study included patients who received IVB injection at Hetauda Community Eye Hospital between January 2019 and December 2022. Inclusion criteria:<InlineEquation ID="IEq1"> <EquationSource Format="TEX">\(\:\ge\:\)</EquationSource> </InlineEquation>1 IVB injection; retinal diagnosis confirmed clinically and by Optical Coherence Tomography (OCT) where available. Exclusion criteria: missing baseline Visual Acuity (VA) or OCT,<InlineEquation ID="IEq2"> <EquationSource Format="TEX">\(\:&lt;1\)</EquationSource> </InlineEquation> month follow-up. Median visual acuity (VA) and central macular thickness (CMT) changes were compared using Wilcoxon signed‑rank test.</p> Results <p>A total of 418 injections were administered to 247 patients (260 eyes). After excluding those lost to follow‑up, 221 patients (234 eyes) were included in the analysis. Median baseline CMT was 366&#xa0;μm and improved to 236&#xa0;μm (<i>p</i> &lt; 0.001). Most patients received one injection (57%) followed by two injections (30%). The median baseline VA was 0.78 log MAR and remained 0.78 log MAR overall (<i>p</i> = 0.108), but subgroup improvements were significant in DME, nAMD, BRVO, and central retinal vein occlusion (CRVO).</p> Conclusion <p>IVB resulted in significant anatomical and functional improvements in patients with retinal diseases. The findings reflect real‑world outcomes in a community‑level eye hospital, where cost barriers limit repeated injections. The limitations of this study include its retrospective design, variable follow‑up, absence of control group, and limited numbers of injections.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Indications and outcome of intravitreal bevacizumab injection in a Community Eye Hospital, Nepal

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月18日

查看全文
  • Sunil Thakali,
  • Mohini Shrestha,
  • Aleena Gauchan,
  • Hom Bahadur Gurung

摘要

Background

This study aimed to evaluate the indications and real-world treatment outcomes of intravitreal bevacizumab in a resource-limited community eye hospital setting.

Methods

This retrospective study included patients who received IVB injection at Hetauda Community Eye Hospital between January 2019 and December 2022. Inclusion criteria: \(\:\ge\:\) 1 IVB injection; retinal diagnosis confirmed clinically and by Optical Coherence Tomography (OCT) where available. Exclusion criteria: missing baseline Visual Acuity (VA) or OCT, \(\:<1\) month follow-up. Median visual acuity (VA) and central macular thickness (CMT) changes were compared using Wilcoxon signed‑rank test.

Results

A total of 418 injections were administered to 247 patients (260 eyes). After excluding those lost to follow‑up, 221 patients (234 eyes) were included in the analysis. Median baseline CMT was 366 μm and improved to 236 μm (p < 0.001). Most patients received one injection (57%) followed by two injections (30%). The median baseline VA was 0.78 log MAR and remained 0.78 log MAR overall (p = 0.108), but subgroup improvements were significant in DME, nAMD, BRVO, and central retinal vein occlusion (CRVO).

Conclusion

IVB resulted in significant anatomical and functional improvements in patients with retinal diseases. The findings reflect real‑world outcomes in a community‑level eye hospital, where cost barriers limit repeated injections. The limitations of this study include its retrospective design, variable follow‑up, absence of control group, and limited numbers of injections.